Audit Ebru Mutlu-Omega CRO. General Purpose to help quality (to maintain quality at present) to assure quality (make sure that quality in future is maintained)

Slides:



Advertisements
Similar presentations
What FDA Looks for When Inspecting IRBs and Sponsors Marian J. Serge Nurse Consultant Division of Bioresearch Monitoring Office of Compliance Center for.
Advertisements

Tips to a Successful Monitoring Visit
How to Survive an FDA Inspection
GCP for Investigators Tina Lidén Mascher, Kvalitetsregister, forskning och industrisamarbeten.
Common Mistakes & Audits 05/21/2014. Summary of audit findings by category.
The IND and Clinical Trial Management Frances Richmond Director International Center for Clinical Trials.
Clinical QA Data Audits A GCP Point of View Linda Del Paggio GCP Compliance BioBridges, LLC.
UTHSC IRB Donna Hollaway, RN, CCRC 11/30/2011 Authority to Audit 45 CFR (e) An IRB shall conduct continuing review of research covered by this.
1st Global QA Conference & 21st SQA Annual Meeting Falcon Consulting Group, LLC 1 Phase I Clinical Study Audits “A Deeper Scrutiny” Cheryl J. Priest, R.N.
Good Clinical Practices Regulatory Guidelines for the Conduct of Clinical research Introduction to Research Pharmacy Services Javier Palacios, R.Ph. Sponsored.
Monitoring and Auditing
Cheryl McCarthy Manager, Quality Assurance MBC Session October 3, 2008 GCP Compliance in our Vendors.
GCP compliance for GenISIS  This presentation is intended for clinical staff involved in recruiting patients to the GenISIS (Genetics of Influenza Susceptibility.
ROLE OF NURSES IN CLINICAL RESEARCH IN MALAWI OWEN DAIRE BSCN MPH RNM.
Pharmacists Responsibilities in Clinical Studies Mike R Sather, PhD Crystal L Harris, PharmD February 26, 2004.
Tipologie di Audit e loro caratteristiche Riunione sottogruppo GCP-GIQAR 21 Marzo 2006 Francesca Bucchi.
Brookhaven Science Associates U.S. Department of Energy 1 Brookhaven National Laboratory Protocol Compliance Monitoring Darcy Mallon May 7, 2009.
MODULE A:MODULE A: Introduction to the CRA/CRC RolesIntroduction to the CRA/CRC Roles Jane FendlJane Fendl March 24, 2010March 24, Version: Final.
Tool Summary Sheet Note: This hidden slide will not show in a slide presentation. Remove before providing slide deck to sites. Tool: Sponsor Responsibilities.
Stanley Estime, MSCI December 9, 2014 Record Keeping: What is Regulatory Documentation and how should it be maintained? Tel:
Strategic Approaches to Outsourcing to Clinical Research Organizations Kate Giovino Director of Clinical Operations.
Healing Hands Clinical Research Services is a Site Management organization with broad spectrum of activities.
Monitoring and Special Considerations for Multi-Center Trials
Regulatory Overview.
Assessment of Interchangeable Multisource Medicines Quality of BE Data Dr. Henrike Potthast Training workshop: Assessment of Interchangeable.
Recapture of Day 1 Suchart Chongprasert, Ph.D. Food and Drug Administration “Practical Aspects in Performing Clinical and Bioanalytical Parts in BA/BE.
Target Institute of Medical Education & Research (TIMER) Provides Clinical Research services to Pharmaceutical, Biotechnology product companies right.
Regulatory Authority Governing Clinical Trials Anthony J. Minisi, MD Director, Cardiology Fellowship Program.
Carolyn Hommel Good Clinical Practice Program FDA February 25, 2004
Janet Ellen Holwell, CCRC, CCRA President, NY Metropolitan Chapter of ACRP.
 WHAT IS AUDIT  PURPOSE OF AUDIT  WHAT IS INSPECTION  DIFFERENCES BETWEEN AUDIT AND INSPECTION  WHO IS RESPONSIBLE FOR AUDIT AND INSPECTION  TYPES.
Audits and Inspections in Clinical Research Jobin Kunjumon Vilapurathu.
Module J Audits and Inspections Patricia E. Koziol 1Module J Final Version 1-May-2010.
Elements of Clinical Trial Quality Assurance Regulatory Coordinator –SCTR SUCCESS Center QA Monitor – NIDA Clinical Trials Network Stephanie Gentilin,
Planning and Surviving An Audit/Monitoring visit Carmen B. Jacobs, BS, RN,OCN, CCRP U.T. MD Anderson Cancer Center Houston, Texas U.S.A.
MODULE I Close-Out Visit/Monitoring Reports Jane Fendl April 24, Versions: Final 24-Apr-2010.
RESCUE: ACRIN 4701 Protocol Development & Regulatory Compliance (PDRC) Josephine Schloesser, ACRIN Monitor Chris Steward, ACRIN QC Auditor.
Joint Research & Enterprise Office Training The team, the procedures, the monitor and the Sponsor Lucy H H Parker Clinical Research Governance Manager.
University of Miami Office of Research Compliance Assessment Lynn E. Smith, JD, CIM, CIP Johanna Stamates, RN, BA, CCRC With assistance from Elizabeth.
Monitoring IRB Monitoring of Clinical Trials. Types of Monitoring Internally Internally Externally Externally.
CLINICAL TRIALS – PHASE III. What are phase III trials  Confirmatory phase (Therapeutic confirmatory trial)  Trials are done to obtain sufficient evidence.
Read the SMALL PRINT of the 1572 The Essential GCP Document.
Quality of Bioequivalence Data Alfredo García - Arieta Training workshop: Training of BE assessors, Kiev, October 2009.
Conducting Clinical Risk Assessments And Implementing Compliance Practices Jane L. Stratton Chiron Corporation VP/Associate General Counsel Chief Compliance.
Overview of Gene Therapy Surveillance Inspections Joseph P Salewski, Chief Bioresearch Monitoring Branch CBER.
Human Subjects Research Office of Responsible Research Practices Human Subjects Research Vanessa Hill, MSHS, CCRC Senior Quality Improvement Specialist.
Module C FDA Regulations Regulatory Documents Patricia E. Koziol 1Module C Final Version 10-apr-2010.
Stanley Estime, MSCI October 19, 2015 Record Keeping: What is Regulatory Documentation and how should it be maintained? Tel:
RIHES-II: H ANDLING A UDITS AND I NSPECTIONS E FFECTIVE D ATE 25 D ECEMBER 2006 V ERSION : 3.0 บุญเหลือ พรึงลำภู 15 มกราคม 2557.
CONDUCTING COMPLIANCE ASSESSMENTS Allen Ditch Director Corporate Quality Bristol Myers Squibb Medical Research Summit March 6, 2003.
Korea Food & Drug Administration Deputy director Kwang-Soo Joo Korea FDA Sep. 29, 2000 : Korean Good Clinical Practice & Relative Guidelines How to Manage.
Session 2 IRB Training  What is the Principal Investigator’s role in Human Subject Research?  What is the role of the Investigator’s staff in Human Subject.
GCP (GOOD CLINICAL PRACTISE)
Responsibilities of Sponsor, Investigator and Monitor
Sponsor Visits and Monitoring Barbara Gallagher, RN Clinical Research Nurse Jefferson Clinical Research Institute.
Briefing on MHRA routine inspection of non-commercial clinical trials
Supervisory Responsibilities of Clinical Investigators
Lisa Hoebelheinrich, JD, CHRC Associate Vice Chancellor, Compliance
The Role and Responsibilities of the Clinical Research Coordinator
Preparing for and Handling Monitoring Visits and Audits
Research Compliance and Institutional Review Boards
Responsibilities of Sponsor, Investigator and Monitor
IRB reporting updates.
Alyssa Speier, MS, CIP November 13, 2013
Reasons for Auditing There are many reasons for auditing. Some examples of these reasons might be: Requested by the IRB Committee Requested by an IRB.
Regulatory Binder: Maintaining Essential Study Documentation
Elements of an Organized Regulatory Binder
Monitoring, Auditing and Compliance
Understanding the Process of Documenting Informed Consent
Good clinical practice
Presentation transcript:

Audit Ebru Mutlu-Omega CRO

General Purpose to help quality (to maintain quality at present) to assure quality (make sure that quality in future is maintained)

Who conduct audits? Sponsor Regulatory Authorities (FDA, EMEA or MOH )

If a clinical trial is being monitored what’s the point of auditing it?

Purpose of sponsor audits ensure that sponsor meets regulatory and GCP requirements ensure that SOPs are followed ensure that the Investigator is following the protocol ensure that the Investigator meets regulatory and GCP requirements

Auditors are independent of and seperate from routine monitoring and quality control functions qualified by training and exprience qualifications should be documented

What type of audit? CRO Investigator site Systems (AE reporting) Trial report Sponsor Database Audits

Which studies? all?? pivotal phase II pivotal phase III CROs

General Criteria for audits importance of trial to regulatory submission number of subjects in trial type and complexity of the trial level of risks to trial subjects indentified problems

Which centers? random selection high recruiters low recruiters for cause preapare for regulatory inspection

When to audit an investigator site? before recruitment after recruitment during recruitment during follow-up after study has completed

Timetable letter (including sites selected for audit) in-house general study file audit in-house investigator file audit pre-field audit discussions with monitor field audit field audit discussions with monitor field audit discussions with investigator,study staff and monitor audit report follow-up action as appropriate

What auditors look for? 1. a complete, legible,visible and robust data trail 2. the requirements of GCP are being met

Top ten audit findings informed consent (not all elements 53%) non-adherance to protocol 30% source documents and CRF entries (inadequate/inaccurate record 25%) drug accountability (inadequate accountability 20%) IRB documentation (problems 12%) documentation and filling patient compliance AE reporting SAE reporting laboratory documentation

Specific audit findings Documentation and filling  inadequate  miss-filling Informed consent  patient’s signature not dated personally  incorrect version of form used  form not signed by the patient prior to study- related procedures performed  back dated signatures on form

Specific audit findings Drug accountability  irregular inventory  incomplete or missing  receipts not signed by sites  CRFs not up to date Laboratory  certification of accreditation  methodology description

What happens after audit? audit report is issued.Draft???

What happens after audit? sponsor and investigator responsible for auctioning recommendations audit report to be filed (where) audit certificate (who)

Regulatory inspections FDA  Between routine 650 for cause

Benefits reassurance opportunities to learn and raise standarts opportunities for process improvement helps keep us on course for regulatory/gcp compliance helps maintain same standarts of quality across different projects(countries) reduces possibility of delays in licensing and marketing of a drug highlights areas where we need to take corrective actions highlights training needs

Your site is being audited!!!!! site contacted from goverment, regulatory authority, sponsor or cro or you are notified before the site is notified verify and ensure regulatory department and project team is aware rewiew of in-house files- obtain any deficient documents review site’s regulatory binder-at site or over phone with site personnel ensure any follow-up items from monitoring reports are completed

Your monitoring has been per ICH/GCP’s and your company SOP’s..... SO THERE IS NOTHING TO FEAR